Weight Management

As demand for GLP-1 therapies grows, patients face rising costs and restrictive insurance policies.

Patients adhering to cagrilintide/semaglutide treatment experienced an average 15.7% weight loss.

A brief period of overeating ultra-processed, high-calorie snacks could lead to liver fat accumulation and temporary disruption of brain insulin action.

Pharmacies could still experience localized availability issues for semaglutide despite its removal from the drug shortage list.

New options for tirzepatide provide a transparent, out-of-pocket choice for patients by streamlining the supply chain and bypassing insurance.

Treatment with semaglutide yielded superior effects on drinking outcomes compared with existing therapies to reduce alcohol cravings.

Using central obesity measures provides more accurate estimates of the proportion of CRC cases attributable to excess weight compared to using BMI alone.

Pharmacists should emphasize the importance of medication adherence and lifestyle changes.

Treatment with 2.4 mg of semaglutide did not increase the risk of developing suicidal ideation or behavior compared with placebo.

The phase 1b/2a results show the potential of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist.

Fractyl Health also reports progress from the REMAIN-1 study evaluating weight management after discontinuing a GLP-1.

The Commission aims to provide information for clinical decision making, therapeutic interventions, and public health strategies.

Approximately 33.2% of patients who received semaglutide 7.2 mg achieved 25% or more weight loss after 72 weeks.

Recommendations help influence the rate of gastric emptying, improve compliance, and prevent interruption of weight loss for patients.

If finalized, the requirement would include readily available nutrition information, including saturated fat, sodium, and added sugar content.

Patients with rheumatoid arthritis and higher body mass index (BMI) showed poorer clinical response to non-tumor necrosis factor (TNF)-targeted treatments.

The data from the report show how nutritional choices compliment the use of glucagon-like peptide-1 receptor agonists and how health care providers can educate patients further.

Fiber-rich foods show improvements in health and reductions in chronic diseases, including obesity, by promoting weight management and enhancing the metabolism.

Some outsourcers and pharmacies have capitalized on the shortages, producing compounded versions.

Despite the explosion of public interest in these drugs, ongoing shortages and debates over compounding made access difficult.

Setmelanotide is indicated to reduce excess body weight and maintain weight reduction long-term for patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome.

Compounding pharmacies have a 60- to 90-day grace period to complete production as it continues to monitor supply and demand.

Results of the study showed an inverse relationship between BMI and LDL cholesterol changes for those who adopt a low-carbohydrate diet.

Pharmacists play an essential role in educating patients about various health-related topics, including type 2 diabetes and nutrition.

The full results will be published in a peer-reviewed journal and presented at a medical meeting next year as the full results are evaluated.

Metabolic bariatric surgery rates has decreased in response to increased use of glucagon-like peptide-1 (GLP-1) receptor agonists.

The combined effects of cagrilintide and semaglutide in CagriSema offer a dual approach to weight loss and glucose regulation.

These findings are significant in understanding interactions between glucagon-like peptide-1 medications and thyroid dysfunction because prior research has shown conflicting results.

The proposed rule would increase access to semaglutide for millions of Americans.